tert-butyl ((3-methylenecyclobutyl)methyl)carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl ((3-methylenecyclobutyl)methyl)carbamate
• 英文别名: tert-butyl N-[(3-methylidenecyclobutyl)methyl]carbamate
• 化学式: C₁₁H₁₉NO₂
• 分子量: 197.277
• InChiKey: OSKYOZFCZDCIJI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.73
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  tert-butyl ((3-methylenecyclobutyl)methyl)carbamate 在 盐酸 、 diethylzinc 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 作用下， 以 1,4-二氧六环 、 二甲基亚砜 、 1,2-二氯乙烷 为溶剂， 反应 5.0h， 生成 4-((5-amino-7-(((3-(2-chloroethyl)cyclobutyl)methyl)amino)-1H-pyrazolo[4,3-d]pyrimidin-1-yl)methyl)-3-methoxy-N-(1-methylpiperidin-4-yl)benzamide
  参考文献：
  名称：

  [EN] 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
  [FR] COMPOSÉS 1H-PYRAZOLO[4,3-D]PYRIMIDINE UTILES EN TANT QU'AGONISTES DU RÉCEPTEUR DE TYPE TOLL 7 (TLR7)

  摘要：

  根据公式I，化合物可作为Toll样受体7（TLR7）的激动剂。这些化合物可用于癌症治疗，特别是与抗癌免疫疗法药物结合使用，或作为疫苗佐剂。

  公开号：

  WO2021154662A1
• 作为产物：
  描述：

  3-亚甲基环丁基甲腈 在 sodium hydroxide 、 lithium aluminium tetrahydride 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 tert-butyl ((3-methylenecyclobutyl)methyl)carbamate
  参考文献：
  名称：

  [EN] ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
  [FR] ANALOGUES D'AMINOGLYCOSIDES ANTIBACTÉRIENS

  摘要：

  结构（I）的化合物具有抗菌活性，包括立体异构体、药用可接受的盐和前药，其中Q1、Q2、Q3、R8和R9如本文所定义。还公开了与制备和使用这些化合物相关的方法，以及包含这些化合物的药物组合物。

  公开号：

  WO2009067692A1

文献信息

• [EN] PYRROLIDINE DERIVATIVES AND THEIR USE AS COMPLEMENT PATHWAY MODULATORS<br/>[FR] DÉRIVÉS PYRROLIDINE ET LEUR UTILISATION EN TANT QUE MODULATEURS DE LA VOIE DU COMPLÉMENT
  申请人：NOVARTIS AG

  公开号：WO2014002054A1

  公开（公告）日：2014-01-03

  The present invention provides a compound of formula (I) a method for manufacturing the compounds of the invention, and its therapeutic uses as complement pathway modulators for the treatment of ocular diseases. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了一种化合物(I)的方法，用于制造该发明的化合物，并将其用作眼部疾病治疗的补体途径调节剂。本发明还提供了一种药理活性剂的组合和制药组合物。
• Process for preparation of intermediates of carbocyclic nucleoside
  申请人：Bristol-Myers Squibb Company

  公开号：US05153352A1

  公开（公告）日：1992-10-06

  A compound of the formula: ##STR1## wherein A is a purin-9-yl group, a heterocyclic isostere of a purin-9-yl group, a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group; E is hydrogen, --CH.sub.2 OH or --OH; and G and D are independently selected from hydrogen, C.sub.1 to C.sub.10 alkyl, --OH, --CH.sub.2 OH, --CH.sub.2 OR.sub.20 wherein R.sub.20 is C.sub.1 to C.sub.6 alkyl, --CH.sub.2 OC(O)R.sub.21 wherein R.sub.21 is C.sub.1 to C.sub.10 alkyl, --CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23) wherein R.sub.22 is the side chain of any of the naturally occuring amino acids and R.sub.23 is hydrogen or --C(O)CH(R.sub.24)(NH.sub.2) wherein R.sub.24 is the side chain of any of the naturally occuring amino acids, --CH.sub.1 SH, --Ch.sub.2 Cl, --Ch.sub.2 F, --CH.sub.2 Br, --CH.sub.2 I, --C(O)H, --CH.sub.2 CN, --CH.sub.2 N.sub.3, --CH.sub.2 NR.sub.1 R.sub.2, --CO.sub.2 R.sub.1, --CH.sub.2 CH.sub.2 OH, --CH.sub.2 CH.sub.2 OR.sub.20 wherein R.sub.20 is as defined above, --CH.sub.2 CH.sub.2 OC(O)R.sub.21 wherein R.sub.21 is as defined above, --CH.sub.2 CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23) wherein R.sub.22 and R.sub.23 are as defined above, --CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2, --Ch.sub.2 OPO.sub.3 H.sub.2, --OCH.sub.2 PO.sub.3 H.sub.2 and --CH.sub.2 CO.sub.2 R.sub.3 wherein R.sub.1 and R.sub.2 are independently selected from hydrogen and C.sub.1 to C.sub.10 alkyl and R.sub.3 is hydrogen, C.sub.1 to C.sub.10 alkyl, carboxyalkyl or aminoalkyl; or a pharmaceutically acceptable salt thereof.

  该化合物的化学式为：##STR1## 其中A是嘌呤-9-基团，嘌呤-9-基团的杂环同分异构体，嘧啶-1-基团或嘧啶-1-基团的杂环同分异构体；E是氢，-CH.sub.2 OH或-OH；G和D分别选择自氢，C.sub.1到C.sub.10烷基，-OH，-CH.sub.2 OH，-CH.sub.2 OR.sub.20，其中R.sub.20是C.sub.1到C.sub.6烷基，-CH.sub.2 OC(O)R.sub.21，其中R.sub.21是C.sub.1到C.sub.10烷基，-CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23)，其中R.sub.22是任何天然氨基酸的侧链，R.sub.23是氢或-C(O)CH(R.sub.24)(NH.sub.2)，其中R.sub.24是任何天然氨基酸的侧链，-CH.sub.1 SH，-Ch.sub.2 Cl，-Ch.sub.2 F，-CH.sub.2 Br，-CH.sub.2 I，-C(O)H，-CH.sub.2 CN，-CH.sub.2 N.sub.3，-CH.sub.2 NR.sub.1 R.sub.2，-CO.sub.2 R.sub.1，-CH.sub.2 CH.sub.2 OH，-CH.sub.2 CH.sub.2 OR.sub.20，其中R.sub.20如上定义，-CH.sub.2 CH.sub.2 OC(O)R.sub.21，其中R.sub.21如上定义，-CH.sub.2 CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23)，其中R.sub.22和R.sub.23如上定义，-CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2，-Ch.sub.2 OPO.sub.3 H.sub.2，-OCH.sub.2 PO.sub.3 H.sub.2和-CH.sub.2 CO.sub.2 R.sub.3，其中R.sub.1和R.sub.2分别选择自氢和C.sub.1到C.sub.10烷基，R.sub.3是氢，C.sub.1到C.sub.10烷基，羧基烷基或氨基烷基；或其药用可接受盐。
• Carbocyclic nucleoside analogs
  申请人：Bristol-Myers Squibb Company

  公开号：US05246931A1

  公开（公告）日：1993-09-21

  A compound of the formula: ##STR1## wherein A is a purin-9-yl group, a heterocyclic isostere of a purin-9-yl group, a pyrimidin-1-yl group or a heterocyclic isostere of a pyrimidin-1-yl group; E is hydrogen, --CH.sub.2 OH or --OH; and G and D are independently selected from hydrogen, C.sub.1 to C.sub.10 alkyl, --OH, --CH.sub.2 OH, --CH.sub.2 OR.sub.20 wherein R.sub.20 is C.sub.1 to C.sub.6 alkyl, --CH.sub.2 OC(O)R.sub.21 wherein R.sub.21 is C.sub.1 to C.sub.10 alkyl, --CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23) wherein R.sub.22 is the side chain of any of the naturally occurring amino acids and R.sub.23 is hydrogen or --C(O)CH(R.sub.24)(NH.sub.2) wherein a R.sub.24 is the side chain of any of the naturally occurring amino acids, --CH.sub.2 SH, --CH.sub.2 Cl, --CH.sub.2 F, --CH.sub.2 Br, --CH.sub.2 I, --C(O)H, --CH.sub.2 CN, --CH.sub.2 N.sub.3, --CH.sub.2 NR.sub.1 R.sub.2, --CO.sub.2 R.sub.1, --CH.sub.2 CH.sub.2 OH, --CH.sub.2 CH.sub.2 OR.sub.20 wherein R.sub.20 is as defined above, --CH.sub.2 CH.sub.2 OC(O)R.sub.21 wherein R.sub.21 is as defined above, --CH.sub.2 CH.sub.2 OC(O)CH(R.sub.22)(NHR.sub.23) wherein R.sub.22 and R.sub.23 are as defined above, --CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2, --CH.sub.2 OPO.sub.3 H.sub.2, --OCH.sub.2 PO.sub.3 H.sub.2 and --CH.sub.2 CO.sub.2 R.sub.3 wherein R.sub.1 and R.sub.2 are independently selected from hydrogen and C.sub.1 to C.sub.10 alkyl and R.sub.3 is hydrogen, C.sub.1 to C.sub.10 alkyl, carboxyalkyl or aminoalkyl; or a pharmaceutically acceptable salt thereof.

  该化合物的化学式为：##STR1## 其中A是嘌呤-9-基团，嘌呤-9-基团的杂环同分异构体，嘧啶-1-基团或嘧啶-1-基团的杂环同分异构体；E是氢，--CH.sub.2 OH或--OH；G和D独立地选择自氢，C.sub.1到C.sub.10烷基，--OH，--CH.sub.2 OH，--CH.sub.2 OR.sub.20，其中R.sub.20是C.sub.1到C.sub.6烷基，--CH.sub.2 OC（O）R.sub.21，其中R.sub.21是C.sub.1到C.sub.10烷基，--CH.sub.2 OC（O）CH（R.sub.22）（NHR.sub.23），其中R.sub.22是任何天然氨基酸的侧链，R.sub.23是氢或--C（O）CH（R.sub.24）（NH.sub.2），其中R.sub.24是任何天然氨基酸的侧链，--CH.sub.2 SH，--CH.sub.2 Cl，--CH.sub.2 F，--CH.sub.2 Br，--CH.sub.2 I，--C（O）H，--CH.sub.2 CN，--CH.sub.2 N.sub.3，--CH.sub.2 NR.sub.1 R.sub.2，--CO.sub.2 R.sub.1，--CH.sub.2 CH.sub.2 OH，--CH.sub.2 CH.sub.2 OR.sub.20，其中R.sub.20如上定义，--CH.sub.2 CH.sub.2 OC（O）R.sub.21，其中R.sub.21如上定义，--CH.sub.2 CH.sub.2 OC（O）CH（R.sub.22）（NHR.sub.23），其中R.sub.22和R.sub.23如上定义，--CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2，--CH.sub.2 OPO.sub.3 H.sub.2，--OCH.sub.2 PO.sub.3 H.sub.2和--CH.sub.2 CO.sub.2 R.sub.3，其中R.sub.1和R.sub.2独立地选择自氢和C.sub.1到C.sub.10烷基，R.sub.3是氢，C.sub.1到C.sub.10烷基，羧基烷基或氨基烷基；或其药学上可接受的盐。
• ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS
  申请人：Aggen James Bradley

  公开号：US20100099661A1

  公开（公告）日：2010-04-22

  Compounds having antibacterial activity are disclosed. The compounds have the following structure (I): including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein Q 1 , Q 2 , Q 3 , R 8 and R 9 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.

  本发明揭示了具有抗菌活性的化合物。这些化合物具有以下结构（I）：包括立体异构体，药学上可接受的盐和其前药，其中Q1、Q2、Q3、R8和R9的定义如本文所述。本发明还揭示了与制备和使用这种化合物相关的方法，以及包含这种化合物的药物组合物。
• COMBINATION THERAPIES USING ANTIBACTERIAL AMINOGLYCOSIDE COMPOUNDS
  申请人：Armstrong Eliana Saxon

  公开号：US20120196791A1

  公开（公告）日：2012-08-02

  Methods for treating a bacterial infection in a mammal in need thereof, and compositions related thereto, are disclosed, the methods comprising administering to the mammal an effective amount of an antibacterial aminoglycoside compound and a second antibacterial agent.

  本文揭示了治疗哺乳动物细菌感染的方法以及相关组合物，该方法包括向哺乳动物施用有效量的抗细菌氨基糖苷化合物和第二种抗细菌药物。